Seric Calprotectine in Spondyloarthritis

Study of the Interest of Serum Calprotectin Determination in the Diagnosis of Spondyloarthritis and to Diferenciate With Fibromyalgia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03818958

Acronym

Calprotect

Enrollment

1000

Registered

2019-01-28

Start date

2017-09-15

Completion date

2018-01-15

Last updated

2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spondylarthritis

Brief summary

To date, there are no biomarkers in spondyloarthritis that can differentiate between spondyloarthritis and fibromyalgia or other pathologies. Fecal calprotectin is a biomarker that is increasingly used in inflammatory diseases of the digestive tract. A growing interest in this biomarker is emerging in rheumatology, several publications have focused on its interest in rheumatoid arthritis, highlighting an association between serum calprotectin levels and disease activity. In spondyloarthritis, a few studies seem to show that it could be a marker of disease activity. Although a 2012 study found no difference in serum calprotectin levels between subjects with spondyloarthritis and controls. Still others have shown that it could be a predictive factor of radiological evolution in the same disease key. These data support, despite the questionable results of the Klingberg study, the value of this dosage in spondyloarthritis. The objective of this work is to show that this assay could be useful to differentiate spondyloarthritis from other pathologies with similar clinical presentation such as fibromyalgia. Difficulties classically encountered in common practice in rheumatology.

Interventions

OTHERblood sampling

blood sampling

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients in the active line of the rheumatology department with one of the following criteria: * active spondyloarthritis (BASDAI \>4), * or spondyloarthritis in low activity (BASDAI\<4), * or fibromyalgia without associated inflammatory rheumatism, * or healthy subjects (without inflammatory rheumatism and without fibromyalgia. * Patients who have not objected to the use of their samples

Exclusion criteria

* Minor patient * Subject not affiliated to the social security system * Subject deprived of liberty * Patient under guardianship or curatorship

Design outcomes

Primary

Measure	Time frame	Description
calprotectine rate	5 months	blood test

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026